JAMA December 03, 2003

A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial

Carl J Pepine, Eileen M Handberg, Rhonda M Cooper-DeHoff, et al.

Bottom Line

The INVEST trial demonstrated that a verapamil-based antihypertensive strategy is clinically equivalent to a standard atenolol-based strategy in preventing adverse cardiovascular events in patients with hypertension and stable coronary artery disease, while carrying a lower risk of new-onset diabetes.

Key Findings

1. At a mean follow-up of 2.7 years, the primary composite outcome (all-cause death, nonfatal MI, or nonfatal stroke) occurred in 9.93% of the verapamil strategy group compared to 10.17% of the atenolol strategy group (RR 0.98; 95% CI 0.90-1.06), establishing equivalence between the two regimens.

2. Blood pressure control at 24 months was similarly robust in both groups, with 65.0% of the verapamil group and 64.0% of the atenolol group achieving JNC VI systolic goals (<140 mm Hg), and over 88% achieving diastolic goals in both arms.

3. The incidence of new-onset diabetes was significantly lower in patients assigned to the verapamil-based strategy compared to those in the atenolol-based strategy (7.03% vs. 8.23%, P < 0.05), highlighting differing metabolic profiles.

Study Design

Design

RCT

Open-Label

Sample

22,576

Patients

Duration

2.7 yr

Median

Setting

14 countries

Population Hypertensive adults aged ≥50 years with documented stable coronary artery disease (CAD)

Intervention Calcium antagonist strategy (CAS) using verapamil SR, supplemented with trandolapril and/or hydrochlorothiazide to achieve blood pressure goals

Comparator Non-calcium antagonist strategy (NCAS) using atenolol, supplemented with hydrochlorothiazide and/or trandolapril to achieve blood pressure goals

Outcome Composite of first occurrence of all-cause death, nonfatal myocardial infarction, or nonfatal stroke

Study Limitations

• The trial utilized a PROBE (Prospective, Randomized, Open-Label, Blinded-Endpoint) design; while endpoints were adjudicated blindly, the open-label nature of drug administration might have introduced medication management bias.

• The study compared complex, multidrug treatment strategies (trandolapril and hydrochlorothiazide were frequently utilized as add-on therapies in both arms) rather than pure monotherapy, making it challenging to isolate the precise independent effects of verapamil and atenolol.

• Patients with recent myocardial infarction, unstable angina, or advanced (NYHA Class IV) heart failure were excluded, meaning these findings cannot be generalized to those acute or severe populations for whom beta-blocker therapy has indisputable survival benefit.

Clinical Significance

INVEST established that a heart rate-lowering calcium channel blocker strategy (verapamil SR) is a safe and effective alternative to a traditional beta-blocker strategy (atenolol) for blood pressure and risk management in patients with stable coronary artery disease. This provided a critical, evidence-based option for secondary cardiovascular prevention in patients with relative contraindications or poor tolerance to beta-blockers. Furthermore, the lower rate of new-onset diabetes with the verapamil strategy emphasized the importance of considering a patient's metabolic risk factors when constructing a long-term antihypertensive regimen.

Historical Context

Prior to the INVEST trial, beta-blockers were the undisputed gold standard for treating hypertension in the setting of coronary artery disease, particularly post-MI. Meanwhile, the safety of calcium channel blockers (CCBs) in CAD was hotly debated; early observational data and studies on short-acting dihydropyridines had suggested a potential increase in cardiovascular mortality. By rigorously testing a long-acting non-dihydropyridine CCB (verapamil SR) against a standard beta-blocker in over 22,000 patients, INVEST definitively dispelled lingering safety concerns regarding long-acting CCBs in stable CAD. It also foreshadowed the eventual paradigm shift recognizing the diabetogenic potential of beta-blockers combined with thiazide diuretics.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

How do the mechanisms of action of verapamil and atenolol differ in reducing myocardial oxygen demand in patients with stable coronary artery disease, and why might their physiological effects lead to similar clinical outcomes in the INVEST trial?

Key Response

Verapamil (a non-dihydropyridine CCB) primarily slows conduction through the AV node, decreases chronotropy, and provides negative inotropy while also promoting vasodilation. Atenolol (a cardioselective beta-1 blocker) reduces heart rate and contractility by antagonizing sympathetic stimulation. Both effectively lower myocardial oxygen demand and increase diastolic filling time, which explains their equivalent efficacy in preventing adverse cardiovascular events in stable CAD, despite acting via different receptor pathways.

Resident

Given the INVEST trial demonstrated equivalence in primary cardiovascular outcomes between verapamil-based and atenolol-based strategies, how should the finding of reduced new-onset diabetes in the verapamil group influence your choice of initial antihypertensive therapy for a patient with stable CAD and metabolic syndrome?

Key Response

While both strategies are highly effective for blood pressure and angina control, beta-blockers (especially when combined with thiazide diuretics, the add-on therapy in the atenolol arm) are known to impair glucose tolerance and increase the risk of new-onset diabetes. In a patient with metabolic syndrome or prediabetes, a verapamil-trandolapril strategy would be clinically preferable to minimize diabetogenic risk while providing equivalent cardioprotection.

Fellow

The INVEST trial used trandolapril as the primary add-on to verapamil and hydrochlorothiazide as the add-on to atenolol. To what extent might the reduction in new-onset diabetes and equivalent cardiovascular protection in the verapamil arm be driven by the renin-angiotensin system blockade rather than the calcium channel antagonist itself?

Key Response

The addition of an ACE inhibitor (trandolapril) in the verapamil arm significantly confounds the ability to attribute the metabolic benefits solely to verapamil. ACE inhibitors are known to improve insulin sensitivity and reduce the risk of incident diabetes compared to beta-blockers and thiazides. Thus, the observed clinical equivalence and superior metabolic profile likely reflect the synergistic benefits of the verapamil-trandolapril combination rather than just the absence of a beta-blocker.

Attending

Historically, beta-blockers were considered an absolute cornerstone for all patients with coronary artery disease. How does the INVEST trial challenge the dogma of universal beta-blocker therapy in stable CAD, and how can we use this to teach trainees about deprescribing or substituting therapies in patients with beta-blocker intolerance?

Key Response

INVEST highlights that in patients with hypertension and stable CAD (without heart failure or recent MI), a non-dihydropyridine CCB strategy is non-inferior to a beta-blocker strategy. This empowers clinicians to confidently substitute verapamil or diltiazem in patients experiencing severe fatigue, erectile dysfunction, or bronchospasm from beta-blockers, teaching trainees that absolute adherence to beta-blockers is only evidence-based for specific subsets (e.g., HFrEF, post-acute MI) rather than all stable CAD.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

The INVEST trial utilized a Prospective Randomized Open Blinded Endpoint (PROBE) design to evaluate the two treatment strategies. What are the methodological advantages and potential sources of bias inherent in using a PROBE design for a trial evaluating complex step-up antihypertensive regimens, and how does this affect the generalizability of the results?

Key Response

The PROBE design closely mimics real-world clinical practice by allowing physicians to titrate medications based on clinical response, which is advantageous for generalizability and pragmatic step-up regimens. However, the lack of double-blinding introduces significant performance bias, as both patients and physicians know the treatment arm, potentially influencing reporting of subjective adverse effects, compliance, and decisions to add non-study medications, even though the primary hard endpoints are adjudicated blindly.

Journal Editor

As a peer reviewer, how would you critically evaluate the study's claim regarding the primary comparison of a 'calcium antagonist vs non-calcium antagonist', given that the majority of patients required combination therapy (trandolapril vs hydrochlorothiazide) to achieve blood pressure control?

Key Response

A rigorous reviewer would flag that INVEST is less a pure comparison of verapamil versus atenolol and more a comparison of two distinct combination strategies (verapamil+ACEi vs. atenolol+thiazide). The title and conclusions framing it primarily as a CCB vs. non-CCB trial are arguably misleading, as the differential effects, particularly regarding new-onset diabetes and equivalent hard endpoints, could largely be attributed to the well-documented metabolic differences between ACE inhibitors and thiazide diuretics.

Guideline Committee

Based on the INVEST trial findings, how should the ACC/AHA guidelines for the management of patients with stable ischemic heart disease and hypertension prioritize the use of non-dihydropyridine calcium channel blockers compared to beta-blockers, specifically regarding Class of Recommendation and Level of Evidence?

Key Response

Current ACC/AHA guidelines for stable ischemic heart disease generally recommend beta-blockers as first-line antianginal therapy (Class I). The INVEST trial provides Level of Evidence A that non-dihydropyridine CCBs are a safe and equally effective alternative for cardiovascular event reduction in hypertensive patients with stable CAD. The guidelines should reflect that verapamil is a Class I or IIa alternative for initial therapy in this population, particularly when beta-blockers are contraindicated, poorly tolerated, or when there is a high risk for incident diabetes, emphasizing that combination therapy is often required.

Clinical Landscape

Noteworthy Related Trials

2002

ALLHAT

n = 33,357 · JAMA

Tested

Amlodipine or Lisinopril

Population

Hypertensive patients aged 55 or older with at least 1 other CHD risk factor

Comparator

Chlorthalidone

Endpoint

Fatal CHD or nonfatal MI

Key result: Thiazide-type diuretics were unsurpassed in lowering blood pressure and reducing clinical complications, supporting their use as preferred first-step therapy.

2005

ASCOT-BPLA

n = 19,257 · Lancet

Tested

Amlodipine-based regimen (+/- perindopril)

Population

Hypertensive patients with at least 3 other cardiovascular risk factors

Comparator

Atenolol-based regimen (+/- bendroflumethiazide)

Endpoint

Non-fatal MI and fatal CHD

Key result: The amlodipine-based regimen prevented more major cardiovascular events and induced less diabetes than the atenolol-based regimen.

2008

ACCOMPLISH Trial

n = 11,506 · NEJM

Tested

Benazepril plus amlodipine

Population

Hypertensive patients at high risk for cardiovascular events

Comparator

Benazepril plus hydrochlorothiazide

Endpoint

Composite of cardiovascular death, nonfatal MI, nonfatal stroke, hospitalization for angina, resuscitated cardiac arrest, and coronary revascularization

Key result: The ACE inhibitor-CCB combination was superior to the ACE inhibitor-diuretic combination in reducing cardiovascular events and morbidity.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis